SLC6神经递质载体抑制的药理机制
Dipanjana Bandyopadhyay1, Smruti Ranjan Nayak1, Aravind Penmatsa2
1Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Advances in neurobiology
|October 6, 2025
概括
溶性载体6家族成员,或神经递质同载体 (NSS),是治疗神经系统疾病的关键标. 本章探讨了NSS载体的各种抑制策略,旨在改善治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 溶解载体6 (SLC6) 家族的成员是神经递质共导体 (NSS),对神经递质在突触空间的再吸收至关重要.
- NSS转运器与各种神经和精神疾病有关,包括抑郁,焦虑,疼痛,成和发作.
- 这些载体是药物开发中的重要治疗点.
研究的目的:
- 探索针对NSS传送器的多种抑制策略.
- 审查现有的抑制剂及其作用机制 (竞争性与全osteric).
- 确定改善治疗应用的抑制策略的潜在领域.
主要方法:
- 关于NSS转运器及其抑制剂的科学文献的综述.
- 分析不同的抑制机制,包括竞争性和全性抑制.
- 探索结构-活动关系和抑制剂设计.
主要成果:
- 通过竞争性或全osteric 机制可以抑制 NSS 载体.
- 抑制剂针对载体的各种形状状态.
- 存在多种类型的抑制剂,其向生物氨基和氨基酸神经递质吸收.
结论:
- 了解各种抑制策略对于开发有效的治疗方法至关重要.
- 准NSS传送器为治疗广泛的神经系统疾病提供了显著的潜力.
- 对新型抑制机制的进一步研究可能会导致改进的治疗剂.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Neurochemical Transmission: Sites of Drug Action
3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Adrenergic Agonists: Indirect-Acting Agents
2.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
Membrane Transporters
17.6K
Transporters are essential membrane transport proteins with functions related to cell nutrition, homeostasis, communication, etc. Approximately 7% of all genes in the human genome code for transporters or transporter-related proteins.
Transporters are mainly composed of alpha-helices, built from bundles of ten or more helices traversing the plasma membrane. The solute-binding sites are located midway, where some of the helices are broken or distorted, making space for the binding site through...
Transporters are mainly composed of alpha-helices, built from bundles of ten or more helices traversing the plasma membrane. The solute-binding sites are located midway, where some of the helices are broken or distorted, making space for the binding site through...
17.6K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
849
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
849


